-

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, will be presenting at 3 upcoming healthcare conferences.

Forte will be presenting at the Guggenheim 2nd Annual Healthcare Innovation Conference at the InterContinental Boston in Boston MA on Mon, Nov 10 at 3:30-3:55 PM ET.

On Nov. 12 at 2:00-2:20 PM ET, Forte will present at the virtual TD Cowen Immunology and Inflammation Summit.

Additionally on Dec 4 at 11:15-11:35 AM ET, Forte will be presenting at the 8th Annual Evercore Healthcare Conference in Coral Gables FL at the Loews Hotel.

Source: Forte Biosciences, Inc.

Contacts

LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Forte Biosciences, Inc.
Paul Wagner, CEO
investors@fortebiorx.com

Industry:

Forte Biosciences, Inc.

NASDAQ:FBRX
Release Versions
English

Contacts

LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Forte Biosciences, Inc.
Paul Wagner, CEO
investors@fortebiorx.com

More News From Forte Biosciences, Inc.

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will...

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s B...

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s B...
Back to Newsroom